Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.
Explore this paper's citation graph
Summary
The CD4 cell count at initiation was the dominant prognostic factor in patients starting HAART, and should be taken into account in future treatment guidelines.
- Type
- article
- Published
- 2002-07-13
- Cited by
- 1,651
- References
- 50
- OpenAlex
- https://openalex.org/W1964622370
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:3253472
Keywords
Medicine, Cohort, Viral load, Internal medicine, Hazard ratio
References
- More rapid progression to AIDS in older HIV-infected people: the role of CD4+ T-cell counts.
- Human Immunodeficiency Virus Type 1 RNA Level and CD4 Count as Prognostic Markers and Surrogate End Points: A Meta-Analysis
- Bayesian measures of model complexity and fit
- Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma
- Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study
- Impact of the AIDS epidemic on morbidity and mortality among intravenous drug users in a New York City methadone maintenance program.
- Association of the CCR5delta32 mutation with improved response to antiretroviral therapy.
- Association of cancer with AIDS-related immunosuppression in adults.
- Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients
- Assessing the Generalizability of Prognostic Information
- Highly active antiretroviral therapy and coronary heart disease: the need for perspective
- CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta‐analysis of studies of the AIDS Clinical Trials Group
- Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
- The need for randomization in the study of intended effects.
- Gender Differences in Virologic Response to Treatment in an HIV‐Positive Population: A Cohort Study
- Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study.
- Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group.
- Immune restoration with antiretroviral therapies: implications for clinical management.
- Impact of opportunistic disease on survival in patients with HIV infection
- The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997. Royal Free Centre for HIV Medicine.
Cited by
- Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts.
- Evaluation of the potential impact of the global economic crisis on HIV epidemics in Southeast Asia
- Short-term CD4 cell response after highly active antiretroviral therapy initiated at different times from seroconversion in 1,500 seroconverters.
- Immune restoration inflammatory syndromes: The dark side of successful antiretroviral treatment
- Determinants of survival following HIV-1 seroconversion after the introduction of HAART.
- Atherosclerotic Cardiovascular Disease Risk in the HAART-Treated HIV-1 Population
- Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program.
- Highly active antiretroviral therapy
- Screening for HIV: A Review of the Evidence for the U.S. Preventive Services Task Force
- Effectiveness and Safety of Abacavir, Lamivudine, and Zidovudine in Antiretroviral Therapy-Naive HIV-Infected Patients: Results From a Large Multicenter Observational Cohort
- Advanced immunosuppression at entry to HIV care in the southeastern United States and associated risk factors
- Highly active anti‐retroviral therapy (HAART)‐induced maintenance of adaptive but not innate immune parameters is associated with protection from HIV‐induced mortality
- Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia
- Impact de différents traitements antirétroviraux (ARV) sur l'évolution des marqueurs d'inflammation et d'activation immunitaire plasmatiques chez les patients infectés par le VIH
- Determinants of HIV Progression and Assessment of the Optimal Time to Initiate Highly Active Antiretroviral Therapy: PISCIS Cohort (Spain)
- Use of predictive markers of HIV disease progression in vaccine trials.
- Use of risk equations for predicting disease progression in HIV infection.
- Clinical audit: virological and immunological response to combination antiretroviral therapy in HIV patients at a Sydney sexual health clinic
- Immunogene Hyperthyreose als Immunrekonstitutionssyndrom unter HIV-Therapie
- Highly active antiretroviral therapy-induced immune recovery in an HIV-positive patient with a history of herpes zoster ophthalmicus.
Related papers
- Near point-of-care HIV viral load testing: Uptake and utilization in suburban Yangon, Myanmar
- Lack of evidence of a stable viral load set‐point in early stage asymptomatic patients with chronic HIV‐1 infection
- Assessment of the Cavidi ExaVir Load Assay for Monitoring Plasma Viral Load in HIV-2-Infected Patients
- The Relation Between Symptoms, Viral Load, and Viral Load Set Point in Primary HIV Infection
- Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure?
- Adaptive viral load monitoring frequency to facilitate differentiated care: a modeling study from Rakai, Uganda.
- Predictive value of the ultrasensitive HIV viral load assay in clinical practice
- 059 Secondary progressive MS in the UK: a prospective cohort study
- Withdrawal of Mycobacterium avium complex suppressive therapy in HIV-1-infected patients on highly active antiretroviral therapy.